Breaking
Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect ProgramEli Lilly's Legal Victory Over Noom's GLP-1 ClaimsBBSW AI Solution Event: Daily Roundup
🇺🇸 FDA

berobenatide News

🇺🇸 Americas ← All news

FDA berobenatide coverage for business development, investment, and market access teams

Latest on berobenatide

Pfizer's Berobenatide: Monthly Obesity Drug Shows Promise in Phase 2b
NewsobesityJun 6, 2026

Pfizer's Berobenatide: Monthly Obesity Drug Shows Promise in Phase 2b

New Phase 2b data for Pfizer's berobenatide (formerly MET097) show robust and continuous weight loss with monthly dosing, reinforcing its potential as a differentiated obesity therapy. The results offer key insights for analysts and BD teams tracking the Pfizer weight loss drug name and the broader obesity pipeline.

Dr. Sarah Mitchell

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.